|Supplied by:||European Collection of Authenticated Cell Cultures (ECACC)|
|Culture Type:||Cell line|
|Collection:||ECACC General Collection|
|Cell Line Name:||fR5|
|Citation Guidance:||If use of this culture results in a scientific publication, it should be cited in the publication as: fR5 (ECACC 98031103)|
|Keywords:||Human breast epithelial, SV40 transformed|
|Cell Line Description:||The breast epithelial cell line fR5 was established in 1982 by infecting suspensions of primary milk cultures with wild-type SV40. The cells do not express Muc-1, also known as HMFG-1 antigen, which is a mucin-like component of human milk fat globule membranes. They are negative for keratins 4, 6, 7, 8, 10, 13 14, 16, 17, 18 and 19. Although fR5 is morphologically different from fR2 (ECACC catalogue no. 98031102), they have probably been derived from a common precursor cell since the karyotypes are similar. Karyotype analysis revealed hypotetraploidy and several rearrangements involving chromosome 1 and 11 which are frequently found in breast carcinomas and lines derived from metastatic pleural effusions. fR5 cells display anchorage independent growth in soft agar and are positive for SV40 T-antigen. Early passages were non-tumourigenic in nude mice.|
|Tissue of Origin:||Breast|
|GMO Status:||Genetically Modified Organism Class 1 (GMO1)|
Unless specified otherwise, at the European Collection of Authenticated Cell Cultures (ECACC) we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines. ACDP = Advisory Committee on Dangerous Pathogens (UK)
All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.
ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Hyperlinks to MSDS documents:
Frozen cell cultures Material Safety Data Sheet
Growing cell cultures Material Safety Data Sheet
Nucleic acids derived from cell cultures Material Safety Data Sheet
|Subculture Routine:||Split sub-confluent cultures (70-80%) 1:10 i.e. seeding 1 x 10,000 cells / cm² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C|
|Culture Medium:||RPMI 1640 + 2mM Glutamine + 10µg/ml insulin + 5µg/ml hydrocortisone + 10% FBS|
|Depositor:||Dr S E Chang and J Taylor-Papadimitriou, Imperial Cancer Research Technology, London|
|References:||Chang SE, Keen J, Lane EB, Taylor-Papadimitriou J 1982 Establishment and characterization of SV40-transformed human breast epithelial cell lines. Cancer Res.42(5):2040-53. PMID: 6279290|
|Additional Bibliography:||Rodgers CS, Hill SM, Hultén MA, Chang SE, Keen J, Taylor-Papadimitriou J.1983 Cytogenetic analysis of SV40-transformed human breast epithelial cells.Cancer Genet Cytogenet. 8(3):213-21.PMID: 6297706. Chang SE. 1986 In vitro transformation of human epithelial cells. Biochim Biophys Acta. 823(3):161-94.PMID: 2423124|
|Patents:||None specified by Depositor|
|Release Conditions:||Yes - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' form|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.
Please confirm your country of origin from the list below.